NO991194D0 - Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid - Google Patents
Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydrokloridInfo
- Publication number
- NO991194D0 NO991194D0 NO991194A NO991194A NO991194D0 NO 991194 D0 NO991194 D0 NO 991194D0 NO 991194 A NO991194 A NO 991194A NO 991194 A NO991194 A NO 991194A NO 991194 D0 NO991194 D0 NO 991194D0
- Authority
- NO
- Norway
- Prior art keywords
- alfa
- methoxyimino
- azabicyclo
- oct
- controlled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9619074.9A GB9619074D0 (en) | 1996-09-12 | 1996-09-12 | Composition |
| PCT/GB1997/002418 WO1998010762A2 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO991194L NO991194L (no) | 1999-03-11 |
| NO991194D0 true NO991194D0 (no) | 1999-03-11 |
Family
ID=10799833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO991194A NO991194D0 (no) | 1996-09-12 | 1999-03-11 | Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0929301A2 (no) |
| JP (1) | JP2001500150A (no) |
| KR (1) | KR20000036039A (no) |
| CN (2) | CN1235544A (no) |
| AR (1) | AR008176A1 (no) |
| AU (1) | AU724086B2 (no) |
| BR (1) | BR9711734A (no) |
| CA (1) | CA2265661A1 (no) |
| CO (1) | CO5031291A1 (no) |
| CZ (1) | CZ83299A3 (no) |
| GB (1) | GB9619074D0 (no) |
| HU (1) | HUP9904401A3 (no) |
| ID (1) | ID19589A (no) |
| IL (1) | IL128781A0 (no) |
| MA (1) | MA24359A1 (no) |
| NO (1) | NO991194D0 (no) |
| NZ (1) | NZ334268A (no) |
| PE (1) | PE2499A1 (no) |
| PL (1) | PL332074A1 (no) |
| TR (1) | TR199900505T2 (no) |
| WO (1) | WO1998010762A2 (no) |
| ZA (1) | ZA978133B (no) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2775597B1 (fr) * | 1998-03-04 | 2001-04-20 | Gattefosse Ets Sa | Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication |
| CN1292696A (zh) | 1998-03-11 | 2001-04-25 | 史密丝克莱恩比彻姆有限公司 | 组合物 |
| DE19918325A1 (de) * | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
| FR2796840B1 (fr) * | 1999-07-26 | 2003-06-20 | Ethypharm Lab Prod Ethiques | Comprimes faiblement doses et procede de preparation |
| US6733781B2 (en) * | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
| US8679533B2 (en) | 2002-07-25 | 2014-03-25 | Pharmacia Corporation | Pramipexole once-daily dosage form |
| US20060252820A1 (en) * | 2003-04-25 | 2006-11-09 | Tetsuya Suzuki | Composition for oral administration containing alkylene dioxybenzene derivative |
| DE602004002405T3 (de) * | 2003-05-14 | 2013-06-20 | Aptalis Pharma Limited | Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand |
| US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| JP2005272347A (ja) * | 2004-03-24 | 2005-10-06 | Ohara Yakuhin Kogyo Kk | 固形製剤の製造方法 |
| WO2006015943A2 (en) | 2004-08-13 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| EP2345407A1 (en) | 2004-08-13 | 2011-07-20 | Boehringer Ingelheim International GmbH | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| EP1970056A1 (en) * | 2007-03-15 | 2008-09-17 | Polichem S.A. | Time-specific delayed/pulsatile release dosage forms |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0392803T3 (da) * | 1989-04-13 | 2004-10-18 | Beecham Group Plc | Hidtil ukendte forbindelser |
| GB9409718D0 (en) * | 1994-05-14 | 1994-07-06 | Smithkline Beecham Plc | Novel compounds |
| GB9421472D0 (en) * | 1994-10-25 | 1994-12-07 | Smithkline Beecham Plc | Novel methods |
| AR004178A1 (es) * | 1995-07-29 | 1998-11-04 | Smithkline Beecham Plc | Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma. |
-
1996
- 1996-09-12 GB GBGB9619074.9A patent/GB9619074D0/en active Pending
-
1997
- 1997-09-08 NZ NZ334268A patent/NZ334268A/xx unknown
- 1997-09-08 PL PL97332074A patent/PL332074A1/xx unknown
- 1997-09-08 AU AU41288/97A patent/AU724086B2/en not_active Ceased
- 1997-09-08 CN CN97199411A patent/CN1235544A/zh active Pending
- 1997-09-08 EP EP97939064A patent/EP0929301A2/en not_active Withdrawn
- 1997-09-08 BR BR9711734A patent/BR9711734A/pt unknown
- 1997-09-08 KR KR1019997002030A patent/KR20000036039A/ko not_active Application Discontinuation
- 1997-09-08 CZ CZ99832A patent/CZ83299A3/cs unknown
- 1997-09-08 IL IL12878197A patent/IL128781A0/xx unknown
- 1997-09-08 JP JP10513352A patent/JP2001500150A/ja active Pending
- 1997-09-08 TR TR1999/00505T patent/TR199900505T2/xx unknown
- 1997-09-08 WO PCT/GB1997/002418 patent/WO1998010762A2/en not_active Application Discontinuation
- 1997-09-08 CA CA002265661A patent/CA2265661A1/en not_active Abandoned
- 1997-09-08 HU HU9904401A patent/HUP9904401A3/hu unknown
- 1997-09-09 CO CO97052280A patent/CO5031291A1/es unknown
- 1997-09-10 ID IDP973137A patent/ID19589A/id unknown
- 1997-09-10 AR ARP970104130A patent/AR008176A1/es not_active Application Discontinuation
- 1997-09-10 MA MA24792A patent/MA24359A1/fr unknown
- 1997-09-10 PE PE1997000805A patent/PE2499A1/es not_active Application Discontinuation
- 1997-09-10 ZA ZA978133A patent/ZA978133B/xx unknown
-
1999
- 1999-03-11 NO NO991194A patent/NO991194D0/no unknown
-
2003
- 2003-01-23 CN CN03102977A patent/CN1446535A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2265661A1 (en) | 1998-03-19 |
| NO991194L (no) | 1999-03-11 |
| CO5031291A1 (es) | 2001-04-27 |
| HUP9904401A3 (en) | 2001-03-28 |
| CN1235544A (zh) | 1999-11-17 |
| ID19589A (id) | 1998-07-23 |
| KR20000036039A (ko) | 2000-06-26 |
| WO1998010762A3 (en) | 1998-06-04 |
| PE2499A1 (es) | 1999-03-24 |
| WO1998010762A2 (en) | 1998-03-19 |
| CZ83299A3 (cs) | 1999-08-11 |
| ZA978133B (en) | 1999-04-12 |
| JP2001500150A (ja) | 2001-01-09 |
| BR9711734A (pt) | 1999-08-24 |
| TR199900505T2 (no) | 1999-06-21 |
| CN1446535A (zh) | 2003-10-08 |
| GB9619074D0 (en) | 1996-10-23 |
| MA24359A1 (fr) | 1998-07-01 |
| HUP9904401A2 (hu) | 2000-06-28 |
| IL128781A0 (en) | 2000-01-31 |
| PL332074A1 (en) | 1999-08-30 |
| AU724086B2 (en) | 2000-09-14 |
| NZ334268A (en) | 2000-10-27 |
| EP0929301A2 (en) | 1999-07-21 |
| AR008176A1 (es) | 1999-12-09 |
| AU4128897A (en) | 1998-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO991194D0 (no) | Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid | |
| IL145071A0 (en) | Fused ring compounds and pharmaceutical compositions containing the same | |
| DE69514087T2 (de) | Pharmazeutisch aktive substituierte aromatische verbindungen | |
| EP1047431A4 (en) | PHARMACEUTICALLY ACTIVE CONNECTIONS AND METHOD FOR THE USE THEREOF | |
| NO990944D0 (no) | Tablett med kontrollert frigivelse av alfuzosinhydroklorid | |
| HUP0004926A3 (en) | 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring, pharmaceutical compositions containing them and their use | |
| EA200200571A1 (ru) | Новая композиция и ее применение | |
| HU9800112D0 (en) | Biphenyl-sulfonyl-substituted heterocyclic compounds of fife-membered ring, their production and use | |
| EA200200119A1 (ru) | β-КАРБОЛИНОВЫЕ ЛЕКАРСТВЕННЫЕ ПРОДУКТЫ | |
| EP1115396A4 (en) | PHARMACEUTICALLY ACTIVE COMPOUNDS, AND METHODS OF USE THEREOF | |
| PL356769A1 (en) | Novel heterocyclic compounds and salts thereof and medicinal use of the same | |
| NO971997D0 (no) | Bruk av immunmodulerende midler | |
| ITMI911604A0 (it) | Procedimento per la preparazione della n- (2,6-diclorofenil) -n-feniln- (cloroacetil) - ammina | |
| EE200100656A (et) | Kristallilise asabitsüklo(2,2,2)oktaan-3-amiintsitraadi polümorfid ja nende ravimsegud | |
| NO992668D0 (no) | Topisk preparat for innf°ring av farmas°ytisk aktive peptidforbindelser i levende organismer | |
| NO20011480L (no) | Fremgangsmåte for fremstilling av (-)<alfa>- (difluormetyl)ornitin-monohydrokloridmonohydrat | |
| NO910372L (no) | Fremgangsmaate for fremstilling av heksahydropyrrolo(2,3-b)indolkarbamater-, urea-, amider og beslektede forbindelser og deres anvendelse som medikamenter. | |
| ATE232103T1 (de) | Osteoblastenspezifische mitogene und diese verbindungen enthaltende arzneimittel | |
| TR199900141T2 (xx) | Bunama tedavisi ve/veya profilaksisi i�in form�lasyon. | |
| NO20010195D0 (no) | Fremgangsmåte for behandling | |
| HUP0004734A3 (en) | Novel pharmaceutically active compounds, their preparation and use as ece-inhibitors | |
| FI933872A (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 1,3,4-bensotriazepin-5(4H)-on-derivat | |
| GB9821967D0 (en) | Process for the preparation of orally active cephalosporin antibiotic-cefixim | |
| GB9821966D0 (en) | Process for the preparation of orally active cephalosporin antibiotic-cefixim | |
| NO20005856L (no) | Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner |